نتائج البحث - "Philipp Le Coutre"

1

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

المصدر: Leukemia

وصف الملف: application/vnd.openxmlformats-officedocument.wordprocessingml.document

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f51ac7fae4b80e1587ed6dbe67919d6Test
https://pubmed.ncbi.nlm.nih.gov/34108614Test

2

Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation

المساهمون: Diral, E, Mori, S, Antolini, L, Abruzzese, E, Le Coutre, P, Martino, B, Pungolino, E, Elena, C, Bergamaschi, M, Assouline, S, Di Bona, E, Gozzini, A, Andrade-Campos, M, Stagno, F, Iurlo, A, Pirola, A, Fontana, D, Petiti, J, Bonanomi, M, Crivori, P, Piazza, R, Fava, C, Gambacorti Passerini, C

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::373ab22048a187785430319d1067b850Test
http://hdl.handle.net/10281/315442Test

3

Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia

المؤلفون: Arlene Reisman, Bfore Study Investigators, Valentín García-Gutiérrez, Charles Chuah, Carlo Gambacorti-Passerini, Andreas Hochhaus, Michael W. Deininger, Dragana Milojkovic, Rocco J. Crescenzo, Tim H. Brümmendorf, Philipp le Coutre, Carla Mamolo, Jorge E. Cortes, Dong-Wook Kim, Michael J. Mauro

المساهمون: Cortes, J, Gambacorti-Passerini, C, Deininger, M, Mauro, M, Chuah, C, Kim, D, Milojkovic, D, le Coutre, P, Garcia-Gutierrez, V, Crescenzo, R, Mamolo, C, Reisman, A, Hochhaus, A, Brummendorf, T

المصدر: Journal of cancer research and clinical oncology. 145(6)

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, medicine.medical_specialty, Health-related quality of life, Population, Newly diagnosed, Drug Administration Schedule, 03 medical and health sciences, 0302 clinical medicine, Quality of life, hemic and lymphatic diseases, Internal medicine, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Surveys and Questionnaires, Nitriles, Medicine, Humans, Patient Reported Outcome Measures, education, Patient-reported outcome, education.field_of_study, Hematology, Aniline Compounds, business.industry, Chronic myeloid leukemia, Cancer, Imatinib, General Medicine, Chronic phase chronic myeloid leukemia, medicine.disease, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Leukemia, Myeloid, Chronic-Phase, Imatinib Mesylate, Quality of Life, Quinolines, Bosutinib, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e16f05ee7c729b1643915c6e699c795Test
https://pubmed.ncbi.nlm.nih.gov/30989330Test

4

Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR

المؤلفون: Chiara Elena, Eros Di Bona, Elisa Diral, Enrico Gottardi, Philipp le Coutre, Alessandra Pirola, Micaela Bergamaschi, Dong-Wook Kim, Jessica Petiti, Alessandra Iurlo, Maria Luisa Bonanomi, Rocco Piazza, Carmen Fava, Patrizia Crivori, Fabio Stagno, Carlo Gambacorti-Passerini, Sarit Assouline

المساهمون: Diral, E, Le Coutre, P, Gottardi, E, Elena, C, Bergamaschi, M, Assouline, S, Di Bona, E, Petiti, J, Stagno, F, Iurlo, A, Kim, D, Pirola, A, Bonanomi, M, Crivori, P, Piazza, R, Fava, C, Gambacorti-Passerini, C

مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, Immunology, Tumor burden, Leukemia Myelogenous Chronic, BCR-ABL Positive, polymerase chain reaction, neoplasms, reverse transcriptase polymerase chain reaction, imatinib mesylate, protein-tyrosine kinase inhibitor, disease remission, Positive control, Biochemistry, 03 medical and health sciences, 0302 clinical medicine, MED/15 - MALATTIE DEL SANGUE, hemic and lymphatic diseases, Internal medicine, medicine, Digital polymerase chain reaction, business.industry, Myeloid leukemia, Imatinib, Cell Biology, Hematology, Discontinuation, 030104 developmental biology, Imatinib mesylate, Functional status, business, 030215 immunology, medicine.drug